Literature DB >> 27638614

Beyond Krabbe's disease: The potential contribution of galactosylceramidase deficiency to neuronal vulnerability in late-onset synucleinopathies.

Michael S Marshall1,2,3, Ernesto R Bongarzone4.   

Abstract

New insights into the pathophysiological mechanisms behind late-onset neurodegenerative diseases have come from unexpected sources in recent years. Specifically, the group of inherited metabolic disorders known as lysosomal storage diseases that most commonly affect infants has been found to have surprising similarities with adult neurodegenerative disorders. Most notable has been the identification of Gaucher's disease as a comorbidity for Parkinson's disease. Prompted by the recent identification of neuronal aggregates of α-synuclein in another lysosomal storage disease, Krabbe's disease, we propose the idea that a similar connection exists between adult synucleinopathies and Krabbe's. Similarities between the two diseases, including the pattern of α-synuclein aggregation in the brain of the twitcher mouse (the authentic murine model of Krabbe's disease), changes to lipid membrane dynamics, and possible dysfunction in synaptic function and macroautophagy, underscore a link between Krabbe's disease and late-onset synucleinopathies. Silent GALC mutations may even constitute a risk factor for the development of Parkinson's in certain patients. More research is required to identify definitively any link and the validity of this hypothesis, but such a connection would prove invaluable for developing novel therapeutic targets for Parkinson's based on our current understanding of Krabbe's disease and for establishing new biomarkers for the identification of at-risk patients.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  Alzheimer's disease; Krabbe's disease; Parkinson's disease; dementia; lysosomal deficiency; neuronal degeneration; psychosine; synaptic failure; α-synuclein

Mesh:

Substances:

Year:  2016        PMID: 27638614      PMCID: PMC5027968          DOI: 10.1002/jnr.23751

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  23 in total

1.  Lipid rafts mediate the synaptic localization of alpha-synuclein.

Authors:  Doris L Fortin; Matthew D Troyer; Ken Nakamura; Shin-ichiro Kubo; Malcolm D Anthony; Robert H Edwards
Journal:  J Neurosci       Date:  2004-07-28       Impact factor: 6.167

2.  Axonopathy is a compounding factor in the pathogenesis of Krabbe disease.

Authors:  Ludovico Cantuti Castelvetri; Maria Irene Givogri; Hongling Zhu; Benjamin Smith; Aurora Lopez-Rosas; Xi Qiu; Richard van Breemen; Ernesto Roque Bongarzone
Journal:  Acta Neuropathol       Date:  2011-03-04       Impact factor: 17.088

Review 3.  Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond.

Authors:  Tamar Shachar; Christophe Lo Bianco; Alessandra Recchia; Christoph Wiessner; Annick Raas-Rothschild; Anthony H Futerman
Journal:  Mov Disord       Date:  2011-05-26       Impact factor: 10.338

4.  Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal.

Authors:  L Maroteaux; J T Campanelli; R H Scheller
Journal:  J Neurosci       Date:  1988-08       Impact factor: 6.167

5.  α-Synuclein inhibits intersynaptic vesicle mobility and maintains recycling-pool homeostasis.

Authors:  David Scott; Subhojit Roy
Journal:  J Neurosci       Date:  2012-07-25       Impact factor: 6.167

Review 6.  Synaptic failure and α-synuclein.

Authors:  Laura Calo; Michal Wegrzynowicz; Jessica Santivañez-Perez; Maria Grazia Spillantini
Journal:  Mov Disord       Date:  2016-01-21       Impact factor: 10.338

7.  Psychosine accumulates in membrane microdomains in the brain of krabbe patients, disrupting the raft architecture.

Authors:  Adam B White; Maria I Givogri; Aurora Lopez-Rosas; Hongmei Cao; Richard van Breemen; Gopal Thinakaran; Ernesto R Bongarzone
Journal:  J Neurosci       Date:  2009-05-13       Impact factor: 6.167

8.  The sphingolipid psychosine inhibits fast axonal transport in Krabbe disease by activation of GSK3β and deregulation of molecular motors.

Authors:  Ludovico Cantuti Castelvetri; Maria I Givogri; Amy Hebert; Benjamin Smith; Yuyu Song; Agnieszka Kaminska; Aurora Lopez-Rosas; Gerardo Morfini; Gustavo Pigino; Mark Sands; Scott T Brady; Ernesto R Bongarzone
Journal:  J Neurosci       Date:  2013-06-12       Impact factor: 6.167

9.  Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro.

Authors:  Jacqueline Burré; Manu Sharma; Theodoros Tsetsenis; Vladimir Buchman; Mark R Etherton; Thomas C Südhof
Journal:  Science       Date:  2010-08-26       Impact factor: 47.728

Review 10.  Examining the mechanisms that link β-amyloid and α-synuclein pathologies.

Authors:  Samuel E Marsh; Mathew Blurton-Jones
Journal:  Alzheimers Res Ther       Date:  2012-04-30       Impact factor: 6.982

View more
  17 in total

Review 1.  Parkinson's disease: proteinopathy or lipidopathy?

Authors:  Saranna Fanning; Dennis Selkoe; Ulf Dettmer
Journal:  NPJ Parkinsons Dis       Date:  2020-01-03

2.  Heterozygote galactocerebrosidase (GALC) mutants have reduced remyelination and impaired myelin debris clearance following demyelinating injury.

Authors:  Nicole J Scott-Hewitt; Christopher J Folts; Jessica M Hogestyn; Gavin Piester; Margot Mayer-Pröschel; Mark D Noble
Journal:  Hum Mol Genet       Date:  2017-08-01       Impact factor: 6.150

Review 3.  The Complicated Relationship between Gaucher Disease and Parkinsonism: Insights from a Rare Disease.

Authors:  Elma Aflaki; Wendy Westbroek; Ellen Sidransky
Journal:  Neuron       Date:  2017-02-22       Impact factor: 17.173

4.  Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration.

Authors:  Conlan Kreher; Jacob Favret; Nadav I Weinstock; Malabika Maulik; Xinying Hong; Michael H Gelb; Lawrence Wrabetz; M Laura Feltri; Daesung Shin
Journal:  PLoS Biol       Date:  2022-07-05       Impact factor: 9.593

Review 5.  Heterozygous carriers of galactocerebrosidase mutations that cause Krabbe disease have impaired microglial function and defective repair of myelin damage.

Authors:  Nicole J Scott-Hewitt; Christopher J Folts; Mark D Noble
Journal:  Neural Regen Res       Date:  2018-03       Impact factor: 5.135

6.  α-Synuclein interacts directly but reversibly with psychosine: implications for α-synucleinopathies.

Authors:  Hazem Abdelkarim; Michael S Marshall; Giuseppe Scesa; Rachael A Smith; Emily Rue; Jeffrey Marshall; Vince Elackattu; Monika Stoskute; Yazan Issa; Marta Santos; Duc Nguyen; Zane Hauck; Richard van Breemen; Maria S Celej; Vadim Gaponenko; Ernesto R Bongarzone
Journal:  Sci Rep       Date:  2018-08-20       Impact factor: 4.379

7.  Inhibition of the IGF-1-PI3K-Akt-mTORC2 pathway in lipid rafts increases neuronal vulnerability in a genetic lysosomal glycosphingolipidosis.

Authors:  Tuba Sural-Fehr; Harinder Singh; Ludovico Cantuti-Catelvetri; Hongling Zhu; Michael S Marshall; Rima Rebiai; Martin J Jastrzebski; Maria I Givogri; Mark M Rasenick; Ernesto R Bongarzone
Journal:  Dis Model Mech       Date:  2019-05-23       Impact factor: 5.758

8.  Analysis of age-related changes in psychosine metabolism in the human brain.

Authors:  Michael S Marshall; Benas Jakubauskas; Wil Bogue; Monika Stoskute; Zane Hauck; Emily Rue; Matthew Nichols; Lisa L DiAntonio; Richard B van Breemen; Jeffrey H Kordower; Carlos A Saavedra-Matiz; Ernesto R Bongarzone
Journal:  PLoS One       Date:  2018-02-26       Impact factor: 3.240

Review 9.  A Focus on the Beneficial Effects of Alpha Synuclein and a Re-Appraisal of Synucleinopathies.

Authors:  Larisa Ryskalin; Carla L Busceti; Fiona Limanaqi; Francesca Biagioni; Stefano Gambardella; Francesco Fornai
Journal:  Curr Protein Pept Sci       Date:  2018       Impact factor: 3.272

Review 10.  Lipids: Key Players That Modulate α-Synuclein Toxicity and Neurodegeneration in Parkinson's Disease.

Authors:  Akio Mori; Yuzuru Imai; Nobutaka Hattori
Journal:  Int J Mol Sci       Date:  2020-05-07       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.